ReGenX

News

 

Please contact
Vit Vasista
for more information.

  • Dr. James M. Wilson Joins REGENXBIO as Chief Scientific Advisor - November 18, 2014

    Download the article (PDF

  • REGENXBIO Appoints Dr. Stephen Yoo as Chief Medical Officer - October 28, 2014

    Download the article (PDF)

  • REGENXBIO’S NAV® Technology Demonstrates Correction of Cardiovascular Symptoms of MPS I - October 01, 2014

    Download the article (PDF)

  • Study Using NAV Vector Highlights Potential for Gene Therapy To Treat Diseases That Affect The CNS - August 27, 2014

    Download the article (PDF)

  • REGENX Biosciences and Voyager Therapeutics Announce License Agreement - June 02, 2014

    Download the Article (PDF)

  • REGENX Biosciences enters into agreement with AAVLife for Friedreich’s ataxia using NAV vectors - April 29, 2014

    Download the article (PDF)

  • REGENX Biosciences and AveXis Enter into Exclusive Agreement for Development of Treatments for SMA - April 01, 2014

    Download the article (PDF)

  • REGENX Biosciences and ESTEVE enter into license agreement for rare lysosomal storage disorder - March 09, 2014

    Download the article (PDF)

  • REGENX and LYSOGENE enter into license agreement for treatment of MPS IIIA using rAAVrh10 vectors - December 05, 2013

    Download the article (PDF)

  • Fidelity Biosciences and REGENX Biosciences Launch Dimension Therapeutics - October 31, 2013

    Download the article (PDF)

  • REGENX Biosciences and Audentes Therapeutics Enter into Exclusive License Agreement - July 30, 2013

    Download the article (PDF)

  • REGENX Biosciences Highlights Progress Using NAV Technology to Prevent Pandemic Influenza - July 16, 2013

    Download the article (PDF)

  • REGENX Biosciences Consortium awarded $7.7M Grant for Clinical Development Program using NAV rAAV8 - March 27, 2013

    Download the article (pdf)

  • REGENX Biosciences Receives FDA Orphan Designation for Treatment of Familial Hypercholesterolemia - April 10, 2012

    Download the article (pdf)

  • REGENX and Asklepios Enter into Agreement for Treatments for Hemophilia A using NAV(TM) rAAV8 - March 08, 2012

    Download the article (pdf)

  • Page 1 of 2 pages  1 2 >